Actively Recruiting
Evaluating Atezolizumab Combined with Selinexor for Treating Alveolar Soft Part Sarcoma in Patients Aged 12 and Older
Led by National Cancer Institute (NCI) · Updated on 2026-10-02
27
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination of atezolizumab and selinexor in patients aged 12 years and older who have alveolar soft part sarcoma ASPS, a rare type of cancer that is difficult to cure with surgery. This phase II trial compares this combination treatment with the usual care options, which include radiation, kinase inhibitors, immunotherapy, or chemotherapy. The study explores if adding these drugs can shrink tumors and improve immune response compared to standard treatments. Participants receive atezolizumab through an intravenous infusion on day 8 of the first 28-day cycle and then on day 1 of each subsequent cycle. Selinexor is given orally on days 1, 8, and 15 of each cycle. Treatment cycles repeat every 28 days unless the disease worsens or side effects become unacceptable. During the study, patients undergo echocardiography before treatment starts, and computed tomography scans along with blood sample collections occur throughout the treatment period. Adult participants may also have tumor biopsies taken to study changes in the cancer. Throughout their participation, patients are monitored for tumor response using standardized imaging criteria and biomarker assessments from biopsies and blood samples. Researchers will follow patients for 30 days after treatment ends to track safety and outcomes. The total participation time includes multiple treatment cycles with ongoing scans and sample collections to evaluate the effects of the drug combination on tumor size and immune activity.
CONDITIONS
Brief Title
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here